Key result
High baseline fibrinogen-to-albumin ratio linked to ~2.1-fold higher risk of poor 3-month stroke outcome.
Why the study?
The prognostic value of fibrinogen-to-albumin ratio (FAR) for 3-month functional outcomes after intravenous thrombolysis in acute ischemic stroke patients was unclear.
Does an elevated baseline fibrinogen-to-albumin ratio (FAR) predict poor 3-month functional outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis?
Observational (n=591)
Single-blind
No
Does an elevated baseline fibrinogen-to-albumin ratio (FAR) predict poor 3-month functional outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis?
Odds Ratio: 2.08 (95% CI 1.28–3.4)
Absolute Event Rate: 41.9% vs 17.9%
p-value: p=0.003
An elevated pre-treatment fibrinogen-to-albumin ratio serves as an independent inflammatory biomarker predicting a poor 3-month functional prognosis in patients with acute ischemic stroke undergoing intravenous thrombolysis.
Should not yet guide thrombolysis decisions in acute ischemic stroke; hypothesis-generating for fibrinogen-to-albumin ratio as a prognostic biomarker.
BACKGROUND: The presence of high fibrinogen and low albumin levels in serum is associated with a negative prognosis in acute ischemic stroke (AIS). Fibrinogen-to-albumin ratio (FAR), a new inflammatory biomarker, may provide better prognostic insights in patients with AIS than separate evaluation of fibrinogen or albumin. The objective of this investigation is to examine the correlation between FAR and 3-month functional prognosis after intravenous thrombolysis (IVT) in AIS patients. METHODS: The retrospective study recruited AIS patients who received IVT from June 2014 to December 2021. The 3-month functional prognosis was assessed using the Modified Rankin Scale (mRS). A mRS score of ≤2 indicated a good outcome, whereas a mRS score of >2 suggested a poor outcome. RESULTS: A total of 591 AIS patients who underwent IVT were included and 147 patients (24.9 %) had a poor outcome. Among the 102 pairs of patients after propensity score matching, there was a significant association between FAR and 3-month prognosis (adjusted OR, 1.19; 95% CI, 1.03-1.38; p = .020). The optimal FAR cutoff value was found to be 7.57, and even after stratifying patients based on this value, we still observed a significant correlation between high FAR level and poor outcome (adjusted OR, 2.08; 95% CI, 1.28-3.40; p = .003). CONCLUSIONS: FAR may serve as a prospective biomarker of predicting 3-month prognosis in AIS patients after IVT.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) conducted an observational in Acute ischemic stroke (AIS) (n=591). High fibrinogen-to-albumin ratio (>7.57) vs. Low fibrinogen-to-albumin ratio (≤7.57) was evaluated on Poor functional prognosis at 3 months (Modified Rankin Scale > 2) (adjusted OR 2.08, 95% CI 1.28-3.40, p=0.003). An elevated baseline fibrinogen-to-albumin ratio (>7.57) was independently associated with an increased risk of poor 3-month functional prognosis in acute ischemic stroke patients after intravenous thrombolysis (adjusted OR 2.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: